Evidence map›Paper›PMID 33330890›Full record

ArticlemedRxiv : the preprint server for health sciences2020

Seroconversion stages COVID19 into distinct pathophysiological states.

Matthew D Galbraith, Kohl T Kinning, Kelly D Sullivan, Ryan Baxter, Paula Araya, Kimberly R Jordan, Seth Russell, Keith P Smith, Ross E Granrath, Jessica Shaw and 8 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Matthew D GalbraithLinda Crnic Institute for Down Syndrome; University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Kohl T KinningLinda Crnic Institute for Down Syndrome; University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Kelly D SullivanLinda Crnic Institute for Down Syndrome; University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Ryan BaxterDepartment of Immunology and Microbiology; University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Paula ArayaLinda Crnic Institute for Down Syndrome; University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Kimberly R JordanDepartment of Immunology and Microbiology; University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Seth RussellData Science to Patient Value; University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Keith P SmithLinda Crnic Institute for Down Syndrome; University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Ross E GranrathLinda Crnic Institute for Down Syndrome; University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Jessica ShawLinda Crnic Institute for Down Syndrome; University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Monika DzieciatkowskaDepartment of Biochemistry and Molecular Genetics; University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Tusharkanti GhoshDepartment of Biostatistics and Informatics, Colorado School of Public Health; University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Andrew A MonteDepartment of Emergency Medicine; University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Angelo D'AlessandroDepartment of Biochemistry and Molecular Genetics; University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Kirk C HansenDepartment of Biochemistry and Molecular Genetics; University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Tellen D BennettDepartment of Pediatrics, Sections of Informatics and Data Science and Critical Care Medicine; University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Elena W Y HsiehDepartment of Immunology and Microbiology; University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Joaquin M EspinosaLinda Crnic Institute for Down Syndrome; University of Colorado Anschutz Medical Campus, Aurora, CO, USA.

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
NIH Prior Approval Process ProfessionalUL1TR002535 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2018 to 2022
$51.1M
Resuscitation Strategies for Achieving Thrombo-inflammatory HomeostasisRM1GM131968 · NIGMS · UNIVERSITY OF COLORADO DENVER · PI COHEN, MITCHELL, D'ALESSANDRO, ANGELO · 2019 to 2023
$11.3M
The Impact of Oxidative Stress on Erythocyte BiologyR01HL148151 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI D'ALESSANDRO, ANGELO, KARAFIN, MATTHEW S · 2019 to 2022
$8.9M
The role of ferroptosis in red cell aging in vivo and in vitroR01HL146442 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI Angelo D'Alessandro, Adam N. Goldfarb · 2019 to 2026
$5.4M
Understanding Down Syndrome as an InterferonopathyR01AI150305 · NIAID · UNIVERSITY OF COLORADO DENVER · PI ESPINOSA, JOAQUIN M. · 2019 to 2020
$3.5M
Interactions between the ADORA2b/Sphk1axis and the AE1-Hb switch in red blood cell aging in vivo and in vitroR01HL149714 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI D'ALESSANDRO, ANGELO · 2020 to 2023
$2.6M
PERSONALIZING EMERGENCY/ACUTE THERAPEUTICS UTILIZING SYSTEMS BIOLOGY (PEGASUS)R35GM124939 · NIGMS · UNIVERSITY OF COLORADO DENVER · PI MONTE, ANDREW ALBERT · 2017 to 2021
$2.1M
MIRAGES: Metabolic Investigation of Red blood cells as a function of Aging, Genetics, Environment, and StorageR21HL150032 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI D'ALESSANDRO, ANGELO · 2020 to 2021
$414k
NCATS NIH HHS UL1 TR002535NCI NIH HHS P30 CA046934NHLBI NIH HHS R01 HL146442NHLBI NIH HHS R01 HL148151NHLBI NIH HHS R01 HL149714NHLBI NIH HHS R21 HL150032NIAID NIH HHS R01 AI150305NIGMS NIH HHS R35 GM124939NIGMS NIH HHS RM1 GM131968
6 · The paper itself

Abstract

COVID19 is a heterogeneous medical condition involving a suite of underlying pathophysiological processes including hyperinflammation, endothelial damage, thrombotic microangiopathy, and end-organ damage. Limited knowledge about the molecular mechanisms driving these processes and lack of staging biomarkers hamper the ability to stratify patients for targeted therapeutics. We report here the results of a cross-sectional multi-omics analysis of hospitalized COVID19 patients revealing that seroconversion status associates with distinct underlying pathophysiological states. Seronegative COVID19 patients harbor hyperactive T cells and NK cells, high levels of IFN alpha, gamma and lambda ligands, markers of systemic complement activation, neutropenia, lymphopenia and thrombocytopenia. In seropositive patients, all of these processes are attenuated, observing instead increases in B cell subsets, emergency hematopoiesis, increased markers of platelet activation, and hypoalbuminemia. We propose that seroconversion status could potentially be used as a biosignature to stratify patients for therapeutic intervention and to inform analysis of clinical trial results in heterogenous patient populations.

Identifiers

PMID33330890
PMCPMC7743101

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.